• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Characteristics of Kawasaki disease in children with a history of COVID-19

tetano

Editor, Senior Moderator
J Infect Chemother


. 2025 Jun 13:102755.
doi: 10.1016/j.jiac.2025.102755. Online ahead of print. Characteristics of Kawasaki disease in children with a history of COVID-19

Hikaru Tabakotani[SUP] 1 [/SUP], Masahiro Ishii[SUP] 1 [/SUP], Masato Ogawa[SUP] 2 [/SUP], Kazuyoshi Mizuki[SUP] 3 [/SUP], Takayuki Hoshina[SUP] 4 [/SUP]



Affiliations
Abstract

Objective: To investigate the characteristics of Kawasaki disease (KD) patients with a history of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, including asymptomatic cases.
Methods: This retrospective study included 63 patients in whom KD was diagnosed between April 2021 and March 2024. We compared demographic and clinical characteristics of patients with KD who did and did not have a history of COVID-19 (KD-COVID-19 vs. KD-non-COVID-19). We also compared these characteristics in the patients who tested positive for the anti-SARS-CoV-2 spike protein antibody in the two groups (antibody-positive KD-COVID-19 vs. antibody-positive KD-non-COVID-19).
Results: Of the 63 patients with KD, 13 had a history of COVID-19. Resistance to initial intravenous immunoglobulin therapy was higher among patients who had had COVID-19 (62%) than among those without COVID-19 (24%; P = 0.017), as were median serum B-type natriuretic peptide (BNP) levels (59.1 vs. 16.0 pg/mL, respectively; P = 0.017). Eight patients (62%) who had had COVID-19 and 16 (32%) who had not had COVID-19 tested positive for the anti-SARS-CoV-2 spike protein antibody. Among patients who were antibody-positive, median serum BNP levels were significantly higher in the patients who had had COVID-19 (76.6 pg/mL) than in those who had not had COVID-19 (14.5 pg/mL; P < 0.001).
Conclusion: Patients with KD who had a history of symptomatic SARS-CoV-2 infection are prone to elevated serum BNP levels, which may indicate potential ventricular dysfunction.

Keywords: B-type natriuretic peptide; COVID-19; Kawasaki disease; anti-SARS-CoV-2 spike IgG antibody; cardiac dysfunction.

 
Back
Top Bottom